Nanoparticle inhaler could reverse chronic lung rejection in transplant patients

This study tested a new inhaled treatment for bronchiolitis obliterans syndrome (BOS), a form of chronic rejection that often occurs after a lung transplant. The treatment uses tiny particles called liposomes to deliver the drug everolimus directly to the lungs, aiming to reduce side effects and possibly reverse the disease. Researchers studied the treatment in lab-grown human lung tissue and in animals, involving 19 participants. The goal is to develop a therapy that can improve long-term survival for lung transplant patients.